Biolidics Ltd. (SG:8YY)
SGX:8YY
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)412.95K
Market Cap
S$107.47M
Enterprise ValueS$109.33M
Total Cash (Recent Filing)S$557.00K
Total Debt (Recent Filing)S$2.41M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Apr 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound / Commercial TractionA near-200% revenue rebound to ~5.3m in 2025 indicates renewed commercial traction and product demand versus a weak prior year. If sustained, the larger revenue base can enable operating leverage, support investment in distribution, and reduce the firm's reliance on external funding over the medium term.
Recurring Consumables Business ModelA business model built on test kits plus per-test consumables creates inherent repeat revenue once an installed base is established. Durable consumable demand supports revenue visibility, higher lifetime customer value, and margin sustainability as unit volumes scale across healthcare providers and laboratories.
Strategic Focus In Diagnostics (POC & Molecular)Focusing on point-of-care and molecular assays places the company in structural growth segments of healthcare diagnostics. Persistent demand for rapid and lab-based infectious disease testing underpins a sizable addressable market and supports long-term partnership, distribution, and scale opportunities.
Bears Say
Persistent Net LossesDespite revenue growth, a ~4.0m net loss in 2025 and consistent annual losses show the business has not reached sustainable profitability. Ongoing losses erode equity over time, limit retained-capital reinvestment, and mean the firm must demonstrate durable margin improvement to avoid recurrent capital raises that constrain strategic flexibility.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicate the core business is not yet self-funding. Even with improvement, ongoing cash burn requires external financing or asset draws, increasing execution risk and potentially delaying reinvestment in commercialization or R&D until cash generation is reliably positive.
Thin Equity And Meaningful LeverageDebt near ~2.4m versus a thin equity cushion (~1.5m) and prior negative-equity years reduces financial flexibility. Limited balance-sheet headroom raises refinancing and solvency risk if operating performance weakens, and increases the likelihood of dilutive capital raises or restrictive covenants that can hamper long-term strategic initiatives.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$107.47M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Apr 24, 2026 which is in 21 days.
How were Biolidics Ltd.’s earnings last quarter?
Biolidics Ltd. released its earnings results on Feb 27, 2026. The company reported -S$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.002.
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Biolidics Ltd. reported an EPS of -S$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.308%.
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biolidics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. The company was incorporated in 2009 and is based in Singapore.
Technical Analysis
HC Surgical Specialists Ltd
―
Hyphens Pharma International Ltd.
―
iX Biopharma Ltd.
―
VicPlas International Ltd.
―
Singapore Paincare Holdings Limited
―